Athersys (NASDAQ:ATHX) has made progress on a number of clinical and commercial fronts in the first months of 2016. Most recently, it reported a one-year follow-up from the Phase II stroke trial, which showed that patients receiving MultiStem improved significantly more than placebo over the course of the year. Also, Athersys and Healios K.K. announced a partnership to commercialize MultiStem in Japan for ischemic stroke with the option to develop other indications. The company expects to initiate a stroke trial in Japan in H216.
MultiStem efficacy improves at one-year follow-up
Athersys released data from a one-year follow-up study to the Phase II ischemic stroke trial. Patients who received MultiStem improved more over the year (to 23.1% excellent outcomes) compared to placebo (8.2%, p=0.02), and the difference was even larger for patients treated early with MultiStem (29.0%, p<0.01). These are the first significant results for the intent-to-treat population.
To read the entire report Please click on the pdf File Below